Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

What Was Tested

This registered phase 4 trial tested Liraglutide.

Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide.

It had three arms (groups): Exercise Alone (experimental), Liraglutide Alone (experimental) and Exercise + Liraglutide (experimental).

24 weeks of treatment.

24 weeks of treatment.

24 weeks f treatment.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 80 planned participants were the target.

It was open to people of any sex aged from 21 years up to 60 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Male or female ≥21 and ≤60 years old. High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic). Calcium channel blockers.

The full record lists 16 inclusion and 10 exclusion criteria; among the exclusions: recently active (\>20 min of moderate/high intensity exercise, 2 times/week); subjects who are smokers or who have quit smoking \<5 years; subjects with bp\>160/90.

How the Study Was Run

It was run as a randomized, factorial and open-label study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Liraglutide study: the participants and staff both knew the treatment.

It started in 2020-11-01 with completion listed for 2027-04-30.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Microvascular Blood Volume - change from baseline (time frame: 24 weeks).

It also tracked 5 secondary outcomes, for example Augmentation Index - change from baseline, Flow Mediated Dilation, Pulse Wave Velocity, Post Ischemic Flow Velocity - change from baseline and Insulin Sensitivity - change from baseline.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Liraglutide in 80 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, all human trials.